Literature DB >> 25903932

Calculations for Adjusting Endogenous Biomarker Levels During Analytical Recovery Assessments for Ligand-Binding Assay Bioanalytical Method Validation.

John F Marcelletti1, Cindy L Evans, Manju Saxena, Adriana E Lopez.   

Abstract

It is often necessary to adjust for detectable endogenous biomarker levels in spiked validation samples (VS) and in selectivity determinations during bioanalytical method validation for ligand-binding assays (LBA) with a matrix like normal human serum (NHS). Described herein are case studies of biomarker analyses using multiplex LBA which highlight the challenges associated with such adjustments when calculating percent analytical recovery (%AR). The LBA test methods were the Meso Scale Discovery V-PLEX® proinflammatory and cytokine panels with NHS as test matrix. The NHS matrix blank exhibited varied endogenous content of the 20 individual cytokines before spiking, ranging from undetectable to readily quantifiable. Addition and subtraction methods for adjusting endogenous cytokine levels in %AR calculations are both used in the bioanalytical field. The two methods were compared in %AR calculations following spiking and analysis of VS for cytokines having detectable endogenous levels in NHS. Calculations for %AR obtained by subtracting quantifiable endogenous biomarker concentrations from the respective total analytical VS values yielded reproducible and credible conclusions. The addition method, in contrast, yielded %AR conclusions that were frequently unreliable and discordant with values obtained with the subtraction adjustment method. It is shown that subtraction of assay signal attributable to matrix is a feasible alternative when endogenous biomarkers levels are below the limit of quantitation, but above the limit of detection. These analyses confirm that the subtraction method is preferable over that using addition to adjust for detectable endogenous biomarker levels when calculating %AR for biomarker LBA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25903932      PMCID: PMC4476982          DOI: 10.1208/s12248-015-9756-2

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  27 in total

1.  Evaluation of a novel ELISA for serotonin: urinary serotonin as a potential biomarker for depression.

Authors:  Mikaela I Nichkova; Han Huisman; Paul M Wynveen; David T Marc; Kelly L Olson; Gottfried H Kellermann
Journal:  Anal Bioanal Chem       Date:  2011-12-10       Impact factor: 4.142

2.  Large molecule specific assay operation: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team.

Authors:  Lauren Stevenson; Marian Kelley; Boris Gorovits; Clare Kingsley; Heather Myler; Karolina Osterlund; Arumugam Muruganandam; Yoshiyuki Minamide; Mario Dominguez
Journal:  AAPS J       Date:  2013-11-16       Impact factor: 4.009

3.  A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon.

Authors:  John H Sloan; Robert W Siegel; Yvelina T Ivanova-Cox; David E Watson; Mark A Deeg; Robert J Konrad
Journal:  Clin Biochem       Date:  2012-08-04       Impact factor: 3.281

4.  Biomarker assay development and validation for large molecules in bioanalysis: what are the challenges and how are they overcome?

Authors:  Lauren F Stevenson
Journal:  Bioanalysis       Date:  2012-11       Impact factor: 2.681

5.  2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines.

Authors:  Binodh DeSilva; Fabio Garofolo; Mario Rocci; Suzanne Martinez; Isabelle Dumont; France Landry; Catherine Dicaire; Gabriella Szekely-Klepser; Russell Weiner; Mark Arnold; Surendra Bansal; Kevin Bateman; Ronald Bauer; Brian Booth; Scott Davis; Sherri Dudal; Dominique Gouty; John Grundy; Sam Haidar; Roger Hayes; Mohammed Jemal; Surinder Kaur; Marian Kelley; Magnus Knutsson; Olivier Le Blaye; Jean Lee; Steve Lowes; Mark Ma; Toshinari Mitsuoka; João Tavares Neto; Robert Nicholson; Eric Ormsby; Jeffrey Sailstad; Lauren Stevenson; Daniel Tang; Jan Welink; C T Viswanathan; Laixin Wang; Eric Woolf; Eric Yang
Journal:  Bioanalysis       Date:  2012-09       Impact factor: 2.681

6.  Recommendations on biomarker bioanalytical method validation by GCC.

Authors:  Richard Hougton; Dominique Gouty; John Allinson; Rachel Green; Mike Losauro; Steve Lowes; Richard LeLacheur; Fabio Garofolo; Philippe Couerbe; Stéphane Bronner; Petra Struwe; Christine Schiebl; Timothy Sangster; Colin Pattison; Rafiq Islam; Wei Garofolo; Maria Pawula; Mike Buonarati; Roger Hayes; Mark Cameron; Robert Nicholson; Jake Harman; Jaap Wieling; Theo De Boer; Scott Reuschel; Laura Cojocaru; Tammy Harter; Michele Malone; William Nowatzke
Journal:  Bioanalysis       Date:  2012-10       Impact factor: 2.681

7.  Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

Authors:  D Richard Lachno; Martin J Romeo; Eric R Siemers; Hugo Vanderstichele; Els Coart; Robert J Konrad; Joseph J Zajac; Jayne A Talbot; Hans F Jensen; Gopalan Sethuraman; Ronald B Demattos; Patrick C May; Robert A Dean
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

8.  Quantitative determination of human interleukin 22 (IL-22) in serum using Singulex-Erenna® technology.

Authors:  Rajiv Shukla; Joseph Santoro; Florent C Bender; Omar F Laterza
Journal:  J Immunol Methods       Date:  2013-01-10       Impact factor: 2.303

9.  A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine.

Authors:  Rebecca L Kift; Michael P Messenger; Tobias C Wind; Sophie Hepburn; Michelle Wilson; Douglas Thompson; Matthew Welberry Smith; Catharine Sturgeon; Andrew J Lewington; Peter J Selby; Rosamonde E Banks
Journal:  Ann Clin Biochem       Date:  2013-05       Impact factor: 2.057

10.  Electrochemical enzyme-linked immunosorbent assay (ELISA) for α-fetoprotein based on glucose detection with multienzyme-nanoparticle amplification.

Authors:  Qin-Lan Liu; Xiao-Hui Yan; Xiao-Mao Yin; Bo Situ; Han-Kun Zhou; Li Lin; Bo Li; Ning Gan; Lei Zheng
Journal:  Molecules       Date:  2013-10-14       Impact factor: 4.411

View more
  2 in total

Review 1.  Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.

Authors:  Darshana Jani; John Allinson; Flora Berisha; Kyra J Cowan; Viswanath Devanarayan; Carol Gleason; Andreas Jeromin; Steve Keller; Masood U Khan; Bill Nowatzke; Paul Rhyne; Laurie Stephen
Journal:  AAPS J       Date:  2015-09-16       Impact factor: 4.009

2.  Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift.

Authors:  Mitra Azadeh; Perceval Sondag; Ying Wang; Maribeth Raines; Jeffrey Sailstad
Journal:  AAPS J       Date:  2019-07-11       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.